Format

Send to

Choose Destination
Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Author information

1
Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen, Bergen, Norway.
2
Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway.
3
Department of Neurology, Norwegian Multiple Sclerosis Registry and Biobank, Haukeland University Hospital, Bergen, Norway.

Abstract

BACKGROUND AND PURPOSE:

There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing-remitting MS (RRMS).

METHODS:

A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015.

RESULTS:

In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed.

CONCLUSIONS:

Based on current knowledge of risk-benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk-benefit stratification.

KEYWORDS:

disease-modifying; multiple sclerosis; review; treatment

PMID:
26563094
PMCID:
PMC4670697
DOI:
10.1111/ene.12883
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center